Clinical meaning
Generalized Anxiety Disorder (GAD) is characterized by persistent, excessive, and difficult-to-control worry about multiple life domains, with the DSM-5 requiring a minimum duration of 6 MONTHS to distinguish it from transient anxiety responses and adjustment disorders. The neurobiological basis involves dysregulation of the cortico-limbic anxiety circuit: the amygdala (threat detection center) becomes hyperactive with lowered activation threshold, while the prefrontal cortex (PFC — responsible for top-down regulation and worry suppression) shows impaired inhibitory control over amygdala output. This creates a feed-forward loop where the amygdala generates excessive fear responses that the PFC cannot adequately suppress. At the neurotransmitter level, GAD involves deficient GABAergic inhibition (GABA is the primary inhibitory neurotransmitter — benzodiazepines enhance GABA-A receptor function for acute relief), serotonergic dysregulation (reduced 5-HT1A receptor binding in the amygdala and raphe nuclei — SSRIs/SNRIs increase serotonergic tone over 4-8 weeks), and noradrenergic hyperactivity (excessive locus coeruleus firing contributes to hyperarousal, muscle tension, and autonomic symptoms). The 6-month duration criterion is clinically critical because it separates GAD (a chronic neurobiological disorder requiring sustained pharmacotherapy and psychotherapy) from adjustment disorder with anxiety (which resolves within 6 months of the stressor's cessation) and from normal stress responses. The chronic nature of GAD reflects neuroplastic changes in the worry circuit — sustained amygdala hyperactivation leads to dendritic remodeling, altered receptor density, and HPA axis dysregulation (elevated cortisol with eventual blunting), which take weeks to months of treatment to reverse. This explains why SSRIs/SNRIs require 4-8 weeks for therapeutic effect (time needed for serotonergic receptor downregulation and neuroplastic reorganization) and why CBT addresses the cognitive distortions (catastrophizing, intolerance of uncertainty) that maintain the dysfunctional circuit. The NP uses the GAD-7 screening tool (sensitivity 89%, specificity 82% at cutoff ≥10) to quantify severity and monitor treatment response, while ruling out medical mimics (hyperthyroidism, pheochromocytoma, caffeine excess, medication-induced anxiety) through targeted laboratory evaluation.